UNSPSC 51142532: Melevodopa

This classification denotes a dopamine agonist with the molecular formula C10H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M30686U4X4, chemically known as l-tyrosine, 3-hydroxy-, methyl ester (9ci) but generally known as melevodopa, which bears US NIH Compound Identifier 23497. European Medicines Agency schedules Melevodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32447.

UNSPSC 51142532 Melevodopa, a Commodity code, does not align with the state and local procurement activity posted under it. The three most recent opportunities tagged to this code solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a multistate cooperative (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target melevodopa specifically, and the activity spans pharmaceutical procurement at the county health-department, state HHS, and multistate cooperative levels. The issuing bodies include a Florida county government, a state health agency, and a regional purchasing alliance administering contracts across multiple states and participating jurisdictions.

Geographic activity is concentrated in Florida, Texas, and Minnesota. The Seminole County naloxone IFB (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) gathers vendor capability information on direct-to-manufacturer prescription programs without a formal evaluation timeline; and the Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, due March 26, 2026) establishes multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026. The code shows minimal relevant recent activity — melevodopa procurement is not explicitly featured in any of the three opportunities, suggesting the code may be mistagged or represents a niche procurement category with limited current state and local demand.